Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Absorption of digoxin in infants.

G Wettrell, K E Andersson

    European Journal of Clinical Pharmacology
    |October 10, 1975
    PubMed
    Summary

    This study examined how well a liquid form of the heart medication digoxin is absorbed into the bloodstream of newborn infants with heart failure. By comparing blood levels after oral and intravenous doses, researchers found that the medication is absorbed effectively, showing similar availability to that seen in adults.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Dilated cardiomyopathy of unknown cause in young patients: risk evaluation, possible etiologies, and treatment.

    The Libyan journal of medicine·2011
    Same author

    Trichobezoar in a child with concomitant coeliac disease: a case report.

    Acta paediatrica (Oslo, Norway : 1992)·2004
    Same author

    Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome.

    Clinical chemistry·2001
    Same author

    [Molecular genetics of the long QT syndrome. Genes causing syncope and sudden death].

    Lakartidningen·2001
    Same author

    Pathophysiology of hypertrophic cardiomyopathy.

    Lancet (London, England)·2001
    Same author

    A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment.

    Journal of the American College of Cardiology·1999

    Area of Science:

    • Pediatric pharmacology research within digoxin pharmacokinetics
    • Clinical cardiology and drug delivery systems

    Background:

    No prior work had resolved the precise oral absorption efficiency of liquid heart medications in neonates experiencing cardiac distress. Clinical practitioners often rely on adult-derived dosing guidelines when treating pediatric populations with chronic conditions. This uncertainty drove the need for direct pharmacokinetic evaluation within this vulnerable patient group. Prior research has shown that physiological differences in the developing gastrointestinal tract can significantly alter drug uptake. However, specific data regarding the systemic availability of this particular glycoside remained sparse. That gap motivated a systematic investigation into how these infants process the therapeutic agent. Understanding these absorption patterns is vital for optimizing safety and efficacy in neonatal care. This study provides a necessary baseline for adjusting pediatric treatment protocols based on empirical evidence.

    Purpose Of The Study:

    The aim of this investigation was to quantify the oral bioavailability of a specific cardiac glycoside in newborn infants. Researchers sought to determine if heart failure affects the absorption efficiency of this medication in the neonatal population. This gap motivated an analysis of how well the drug enters the bloodstream when delivered orally. The team wanted to compare these results against established intravenous pharmacokinetic profiles. By examining these parameters, the authors intended to clarify whether pediatric dosing requires significant modification from adult standards. That uncertainty drove the need for precise measurements of serum concentrations over time. The study addresses the clinical concern regarding the therapeutic reliability of oral treatments in infants. This work provides a foundation for understanding drug uptake dynamics in patients with compromised cardiac function.

    Keywords:
    neonatal pharmacologybioavailabilityheart failure treatmentserum concentration

    Frequently Asked Questions

    The researchers determined bioavailability by comparing the areas under the serum concentration curves over an eight-hour period. This method involved measuring drug levels in the blood following both intravenous and oral administration within the same subjects.

    The study utilized radioimmunoassay with iodine-125 to quantify the concentration of the glycoside in serum samples. This analytical tool allowed for precise tracking of drug levels over time.

    Intravenous administration was necessary to establish a reference point for 100 percent bioavailability. This route allows for a direct comparison against oral dosing to determine the fraction of the drug that reaches systemic circulation.

    The researchers analyzed serum concentration curves to assess drug kinetics. These data points provided the basis for calculating the mean bioavailability of 72 percent observed in the infants.

    Related Experiment Videos

    Main Methods:

    The investigators conducted a clinical assessment involving four newborn infants diagnosed with heart failure. Each participant received a standardized dose of 0.05 milligrams per kilogram of body weight. The team administered the glycoside through both oral and intravenous routes to facilitate a within-subject comparison. They collected serial blood samples to monitor systemic drug levels over an eight-hour duration. Laboratory staff utilized radioimmunoassay techniques to quantify the concentration of the substance in the serum. The review approach focused on calculating the area under the curve for both delivery methods. This design allowed for the determination of the fraction of the dose reaching the systemic circulation. The researchers performed these measurements to evaluate the efficiency of gastrointestinal uptake in the neonatal subjects.

    Main Results:

    The key findings from the literature reveal a mean bioavailability of 72 percent for the oral solution. Individual results ranged from 52 to 79 percent across the four infants studied. Peak serum concentrations between 2.3 and 4.4 nanograms per milliliter occurred within 30 to 90 minutes post-ingestion. Intravenous administration resulted in a rapid initial decline in blood levels during the first two hours. After four hours, the intravenous concentration profiles mirrored those observed following oral intake. The data indicate that the medication is well absorbed despite the presence of mild to moderate heart failure. These results demonstrate that the systemic availability in neonates is comparable to that documented in adult populations. The study provides quantitative evidence supporting the consistent performance of the drug across different age groups.

    Conclusions:

    The researchers propose that liquid formulations of this medication exhibit high systemic uptake in neonates. This evidence suggests that pediatric patients with mild to moderate cardiac issues achieve therapeutic levels comparable to mature individuals. The synthesis of these findings implies that standard dosing strategies may remain appropriate for this demographic. Clinicians should note that the observed absorption rates align with established pharmacological expectations for adults. The authors highlight that the medication remains biologically active and accessible after oral delivery. This review indicates that the gastrointestinal environment in these infants does not hinder the absorption of the glycoside. Future clinical practice might benefit from these insights when managing heart failure in early life. The study confirms that oral administration is a viable route for delivering this treatment effectively.

    Peak serum values ranged from 2.3 to 4.4 nanograms per milliliter. These levels were achieved within a timeframe of 30 to 90 minutes following the oral dose.

    The authors propose that their findings support the use of standard oral dosing for infants with heart failure. They suggest that the medication is absorbed as effectively in this group as it is in adults.